Abbott Laboratories vs Stryker
Abbott Laboratories reported revenue of $44.3 billion in fiscal 2025, 1.8 times Stryker's $25.1 billion in fiscal 2025. Abbott Laboratories' revenue grew 5.7% in its latest year, and Stryker's grew 11.2%. Abbott Laboratories had an operating margin of 18.2%, against 19.5% at Stryker. Free cash flow was $7.4 billion at Abbott Laboratories and $4.3 billion at Stryker.
Side by side
| Abbott Laboratories | Stryker | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $44.3B | $25.1B |
| Revenue growth | 5.7% | 11.2% |
| Revenue growth a year, last 5 years | 5.1% | 11.8% |
| Gross margin | 56.4% | 64.0% |
| Operating margin | 18.2% | 19.5% |
| Net margin | 14.7% | 12.9% |
| Free cash flow | $7.4B | $4.3B |
| Free cash flow margin | 16.7% | 17.1% |
| Return on capital | 11.2% | 11.3% |
| Net debt to EBITDA | 0.4x | 1.7x |
| Dividends and buybacks | $5.0B | $1.3B |
| Change in diluted share count | 0.0% | 0.2% |
| Last close | $104.88 | $306.13 |
| P/E at the last close | 29.3× | 31.7× |
| Insider trades, last 12 months | bought $4.4 million, sold $47.5 million | sold $586.1 million |
| Piotroski F-score | 6 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Abbott LaboratoriesStryker
Operating margin
Percent of revenue
Abbott LaboratoriesStryker
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Abbott LaboratoriesStryker
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Abbott Laboratories and Stryker pages.